These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31040165)

  • 1. NSD2 silencing alleviates pulmonary arterial hypertension by inhibiting trehalose metabolism and autophagy.
    Zhou XL; Liu ZB; Zhu RR; Huang H; Xu QR; Xu H; Zeng L; Li YY; Huang CH; Wu QC; Liu JC
    Clin Sci (Lond); 2019 May; 133(9):1085-1096. PubMed ID: 31040165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of AMPK prevents monocrotaline-induced pulmonary arterial hypertension by suppression of NF-κB-mediated autophagy activation.
    Zhai C; Shi W; Feng W; Zhu Y; Wang J; Li S; Yan X; Wang Q; Zhang Q; Chai L; Li C; Liu P; Li M
    Life Sci; 2018 Sep; 208():87-95. PubMed ID: 30009823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting vascular remodeling in rats.
    Shi R; Wei Z; Zhu D; Fu N; Wang C; Yin S; Liang Y; Xing J; Wang X; Wang Y
    Pulm Pharmacol Ther; 2018 Feb; 48():124-135. PubMed ID: 29133079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of cordycepin in the treatment of pulmonary arterial hypertension in rats based on metabonomics and transcriptomics.
    Lin J; Chen R; Liao H; Zhang Y; Zheng Z; Hong C
    Sci Rep; 2024 May; 14(1):12431. PubMed ID: 38816406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.
    Mulvaney EP; Reid HM; Bialesova L; Bouchard A; Salvail D; Kinsella BT
    BMC Pulm Med; 2020 Apr; 20(1):85. PubMed ID: 32252727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
    Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Shp2 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats.
    Cheng Y; Yu M; Xu J; He M; Wang H; Kong H; Xie W
    BMC Pulm Med; 2018 Aug; 18(1):130. PubMed ID: 30086741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydromyricetin prevents monocrotaline-induced pulmonary arterial hypertension in rats.
    Li Q; Wang J; Zhu X; Zeng Z; Wu X; Xu Y; Xie J; Yu J
    Biomed Pharmacother; 2017 Dec; 96():825-833. PubMed ID: 29078260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of Autophagy Induces Monocrotaline-Induced Pulmonary Arterial Hypertension by FOXM1-Mediated FAK Phosphorylation.
    Zhai C; Zhang N; Wang J; Cao M; Luan J; Liu H; Zhang Q; Zhu Y; Xue Y; Li S
    Lung; 2022 Oct; 200(5):619-631. PubMed ID: 36107242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel alleviates monocrotaline-induced pulmonary arterial hypertension via inhibition of FoxO1-mediated autophagy.
    Feng W; Wang J; Yan X; Zhai C; Shi W; Wang Q; Zhang Q; Li M
    Naunyn Schmiedebergs Arch Pharmacol; 2019 May; 392(5):605-613. PubMed ID: 30683943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats.
    Leong ZP; Hikasa Y
    Vascul Pharmacol; 2018 Nov; 110():31-41. PubMed ID: 30071297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formononetin attenuates monocrotaline‑induced pulmonary arterial hypertension via inhibiting pulmonary vascular remodeling in rats.
    Cai C; Xiang Y; Wu Y; Zhu N; Zhao H; Xu J; Lin W; Zeng C
    Mol Med Rep; 2019 Dec; 20(6):4984-4992. PubMed ID: 31702810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Notch3 prevents monocrotaline-induced pulmonary arterial hypertension.
    Zhang Y; Xie X; Zhu Y; Liu L; Feng W; Pan Y; Zhai C; Ke R; Li S; Song Y; Fan Y; Fan F; Wang X; Li F; Li M
    Exp Lung Res; 2015; 41(8):435-43. PubMed ID: 26317171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
    Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
    Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymoquinone attenuates monocrotaline-induced pulmonary artery hypertension via inhibiting pulmonary arterial remodeling in rats.
    Zhu N; Zhao X; Xiang Y; Ye S; Huang J; Hu W; Lv L; Zeng C
    Int J Cardiol; 2016 Oct; 221():587-96. PubMed ID: 27420584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
    Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
    Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Betaine Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats via Inhibiting Inflammatory Response.
    Yang JM; Zhou R; Zhang M; Tan HR; Yu JQ
    Molecules; 2018 May; 23(6):. PubMed ID: 29861433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alginate Oligosaccharide Alleviates Monocrotaline-Induced Pulmonary Hypertension via Anti-Oxidant and Anti-Inflammation Pathways in Rats.
    Feng W; Hu Y; An N; Feng Z; Liu J; Mou J; Hu T; Guan H; Zhang D; Mao Y
    Int Heart J; 2020 Jan; 61(1):160-168. PubMed ID: 31956132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of HDAC1 alleviates monocrotaline-induced pulmonary arterial remodeling through up-regulation of miR-34a.
    Li F; Wang D; Wang H; Chen L; Sun X; Wan Y
    Respir Res; 2021 Aug; 22(1):239. PubMed ID: 34465322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension.
    Chowdhury B; Luu AZ; Luu VZ; Kabir MG; Pan Y; Teoh H; Quan A; Sabongui S; Al-Omran M; Bhatt DL; Mazer CD; Connelly KA; Verma S; Hess DA
    Biochem Biophys Res Commun; 2020 Mar; 524(1):50-56. PubMed ID: 31980166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.